Los Angeles Allergist

Los Angeles Allergist

Alan Khadavi, MD, APC
  • Home
  • Meet Dr. Khadavi
  • Conditions We Treat
  • Your First Visit
  • Insurance Accepted
  • Allergy and Asthma Info
    • Asthma Info
    • Allergic Rhinitis
    • Allergic Triggers
  • Blog
  • Media
  • Contact Us

9001 Wilshire Blvd. Suite 204
Beverly Hills, CA 90211
Phone: 310-282-8822

16260 Ventura Blvd., Suite 140
Encino, CA 91436
Phone: 818-528-7776

August 11, 2020 by Alan Khadavi

Covid with Xolair, Nucala, Cinaqir, Fasenra or Dupixent for Asthma

As Covid-19 continues to spread around the world, there are concerns that patients with asthma will be at higher risk or poorer outcomes. There is also concern about whether asthma treatments could worsen the risk of disease or severity.

Currently, asthma is not in the top 10 comorbidities associated with Covid-19 fatalities, obesity, diabetes and chronic heart disease are the most common.

There are questions of concern that relate to the effects that asthma medications may have on Covid infections. Inhaled steroids are the mainstay of treatment of persistent asthma and oral steroids are given during acute exacerbations.

Both the American College of Allergy, Asthma and Immunology and the American Academy of Allergy, Asthma and Immunology recommend that patients continue to use their maintenance asthma medications even during the pandemic. Continuation of therapy even with potential exposure to COVID-19 is extremely important because poorly controlled asthma is always the greatest risk factor for exacerbations with any viral illness.

With regard to biologics approved for asthma treatment on the risk of COVID-19, effects may differ.

Xolair (omalizumab), blocks an IgE antibody. Nucala (mepolizumab) and Cinqair (reslizumab) blocks Interleukin-5. Fasenra (benralizumab) blocks the IL-5 receptor and Dupixent (dupilumab)  blocks the IL-4 receptor alpha, a receptor shared by IL-4 and IL-13. They all reduce asthma-related exacerbations and have been approved for the treatment of severe asthma. Approximately 80% of asthma exacerbations are related to viral infections. It is likely that these biologics will lessen the risk of severe asthma exacerbations with COVID-19, at least by reducing baseline airway inflammation and possibly through specific antiviral properties.

With the knowledge of how the currently approved biologics work, it does not seem that these medications would interfere adversely with any of the pathways or worsen an individual’s immune response to COVID-19. It is actually plausible that these biologics, by limiting Th2 skewing, may make the immune system better poised to clear SARS-CoV-2.

In conclusion, the currently approved biologic medications for severe asthma (Xolair, Nucala, Fasenra, Cinqair and Dupixent) do not increase the risk of disease or worse outcomes. On the contrary they lead to improvement of airway allergic and eosinophilic inflammation and bronchial responsiveness which could be advantageous in patients with asthma who are already taking these medications before contracting COVID-19.

Filed Under: biologics, Blog

alan-khadavi
Dr. Alan Khadavi
Allergy & Asthma Specialist

Latest Posts

January 16, 2021

Singulair psychiatric side effects; a large study

Singulair psychiatric side effects

January 11, 2021

Allegra during Pregnancy, is it safe?

allegra during pregnancy

December 25, 2020

Moderna Covid Vaccine and Allergy

moderna covid vaccine and allergy

December 12, 2020

Pfizer Covid Vaccine and Allergy

covid vaccine and allergy

December 3, 2020

Budesonide Oral Suspension for Eosinophilic Esophagitis

budesonide oral suspension

December 1, 2020

Indacaterol for severe asthma

indacaterol

November 3, 2020

New treatments for chronic hives

New treatments for chronic hives

October 29, 2020

Xolair for Allergic Rhinitis-A recent study

xolair for allergic rhinitis

October 26, 2020

Semen allergy an overview and treatment

semen allergy

October 21, 2020

Peanut Patch (Viaskin) for peanut allergy

viaskin peanut patch

Read More Posts...

Follow Us…

© 2021 Allergy Los Angeles. All Rights Reserved · Log in · Return to top of page